Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Journey Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Journey Medical's regulatory disclosures and financial reporting.
Journey Medical Corporation reported a major expansion in payer coverage for Emrosi™, its oral treatment for inflammatory lesions of rosacea in adults. After securing a contract with a third major group purchasing organization, Emrosi™ payer access increased from approximately 100 million to over 150 million commercial lives as of April 1, 2026.
The company states that about 85% of all commercial lives in the United States now have access to Emrosi™, which it expects will support growth in total prescriptions, broader formulary adoption through 2026 and beyond, and reduced reliance on its co-pay bridging program.
Journey Medical Corp ownership disclosure: Wasatch Advisors reports beneficial ownership of 2,133,370 shares, representing 10.0% of the common stock as reported 03/31/2026. The filing shows sole voting power for 1,979,366 shares and sole dispositive power for 2,133,370 shares.
Journey Medical Corporation outlines its dermatology-focused business in its annual report, highlighting a portfolio of eight FDA‑approved prescription products and several legacy brands. The company concentrates on acne, rosacea, hyperhidrosis, fungal infections, pruritus and wound care, selling mainly through specialty pharmacies and distributors in the U.S.
In 2024 the FDA approved Emrosi, a low‑dose oral minocycline for rosacea, which launched commercially in 2025 and is protected by patents through 2039. Journey also markets Qbrexza, Amzeeq, Zilxi and Accutane under multiple in‑license and acquisition agreements that include milestones and royalties.
The report emphasizes growth via additional product licenses and acquisitions, notes new out‑licensing deals in Asia, and describes reliance on third‑party manufacturers and partners. It also details extensive intellectual property, regulatory and healthcare compliance frameworks, and key risks such as generic competition, pricing pressure, and Fortress Biotech’s voting control.
Journey Medical Corporation reported full-year 2025 results with total revenues of $61.9 million, up from $56.1 million in 2024. Net loss narrowed to $11.4 million compared with $14.7 million a year earlier, and GAAP net loss per share improved to $0.47 from $0.72.
The company generated non-GAAP Adjusted EBITDA of $2.9 million, up from $0.8 million in 2024, reflecting higher product revenue and lower research and development spending. Cash and cash equivalents were $24.1 million as of December 31, 2025, compared with $20.3 million at year-end 2024.
Management highlighted the launch of Emrosi™, which generated $14.7 million in net revenues in 2025 after its early April launch, with approximately 53,000 prescriptions filled and payer access to over 100 million U.S. commercial lives.
Journey Medical Corporation is launching an at-the-market offering of up to 3,750,000 shares of common stock under a sales agreement with B. Riley Securities and Lake Street Capital. The shares may be sold from time to time on The Nasdaq Capital Market at prevailing prices, with the Agents receiving a 3.0% commission on gross proceeds and being deemed underwriters. If all shares were sold at a recent price of $7.27, the company illustrates potential gross proceeds of about $27.3 million and an increase in net tangible book value per share, but also immediate dilution of $6.49 per share to new investors. Journey plans to use any net proceeds for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, and capital expenditures. The company highlights that investors face dilution risk, stock price volatility from ongoing ATM sales, and that an independent auditor has raised substantial doubt about its ability to continue as a going concern.
Journey Medical Corporation has filed a shelf registration that allows it to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The company can sell these securities in one or more offerings, separately or bundled in units, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds may be used for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, administrative expenses and capital expenditures. Journey is a commercial-stage pharmaceutical company focused on FDA-approved dermatology products, including the recently approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for inflammatory lesions of rosacea in adults. The company is controlled by Fortress Biotech through Class A Common Stock with majority voting power and is classified as both an emerging growth company and a smaller reporting company. The independent auditor’s report on the 2024 financial statements includes an explanatory paragraph noting recurring losses from operations that raise substantial doubt about Journey’s ability to continue as a going concern.
Journey Medical Corporation has filed a shelf registration that allows it to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units over time. Within this shelf, the company established an at‑the‑market program to sell up to 3,750,000 shares of common stock through B. Riley Securities and Lake Street Capital Markets, which will earn a 3.0% commission on gross proceeds. Shares will be issued at prevailing market prices on Nasdaq, where the stock trades under the symbol “DERM” and last closed at $7.27 on January 9, 2026.
Journey plans to use any proceeds for general corporate purposes, including working capital, research and development, sales and marketing, operating expenses, capital expenditures, and potential acquisitions or in‑licensing of additional dermatology products. The company is a commercial‑stage dermatology pharmaceutical business with eight FDA‑approved prescription products and a newly approved rosacea drug, Emrosi, and it remains an emerging growth and smaller reporting company controlled by Fortress Biotech. Its most recent audited financial statements include an auditor’s going concern explanatory paragraph citing recurring losses from operations.
Journey Medical reported Q3 2025 results. Total revenue was $17.631 million, up 21% year over year, with product revenue of $17.025 million. Net loss narrowed to $2.315 million (basic and diluted loss per share of $0.09).
Emrosi contributed $4.883 million as its U.S. launch scaled, while Qbrexza delivered $7.361 million. Accutane declined to $2.769 million amid competition. The company also recognized $0.606 million of other revenue from supplying Amzeeq to Cutia.
Cash and cash equivalents were $24.948 million and working capital was $16.7 million as of September 30, 2025. Year-to-date, the company raised $10.939 million via its ATM program (including $6.891 million in Q3). Term loan principal remained $25.0 million; effective interest was 14.47%.
On September 25, 2025, Journey amended its SWK Credit Facility, extending maturity to June 27, 2028 and lowering the revenue threshold for extending the interest-only period to $60.0 million on a trailing twelve-month basis. The company stated that, due to recurring and historical losses, substantial doubt exists about its ability to continue as a going concern.
Journey Medical Corporation furnished a press release providing a corporate update and its financial results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 to this report.
The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” under the Exchange Act, and will not be incorporated by reference into Securities Act filings except as specifically referenced. The company’s common stock trades on the Nasdaq Capital Market under the symbol DERM.